CRISPR Therapeutics AG (CRSP) has a negative trailing P/E of -8.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 19.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -12.48%, forward earnings yield 5.18%. PEG 0.04 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 48/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -10.7 | -0.09 | 1.07 | 48.09 | - |
| 2017 | -13.7 | 1.44 | 5.00 | 22.89 | - |
| 2018 | -8.3 | -0.08 | 3.49 | 438.61 | - |
| 2019 | 49.5 | -0.36 | 3.53 | 11.44 | - |
| 2020 | -28.9 | 0.05 | 6.07 | 14,043.89 | - |
| 2021 | 15.2 | -0.08 | 2.40 | 6.30 | - |
| 2022 | -4.9 | 0.02 | 1.69 | 7,248.62 | - |
| 2023 | -32.3 | 0.42 | 2.63 | 13.40 | - |
| 2024 | -9.1 | -0.07 | 1.72 | 94.87 | - |
| 2025 | -8.1 | -0.17 | 2.45 | 1,343.50 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-1.89 | $5.16M | $-23.2M | -449.3% |
| 2017 | $-1.71 | $41M | $-68.36M | -166.7% |
| 2018 | $-3.44 | $3.12M | $-164.98M | -5281.1% |
| 2019 | $1.17 | $289.59M | $66.86M | 23.1% |
| 2020 | $-5.29 | $543K | $-348.87M | -64247.7% |
| 2021 | $4.70 | $913.08M | $377.66M | 41.4% |
| 2022 | $-8.36 | $436K | $-650.18M | -149122.7% |
| 2023 | $-1.94 | $371.21M | $-153.61M | -41.4% |
| 2024 | $-4.34 | $35M | $-366.25M | -1046.4% |
| 2025 | $-6.47 | $3.51M | $-581.6M | -16569.8% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.86 | $-6.42 – $-2.28 | $45.14M | $2.73M – $208.13M | 20 |
| 2027 | $-3.85 | $-5.95 – $-0.54 | $142.43M | $2.19M – $557.44M | 16 |
| 2028 | $-2.47 | $-11.73 – $12.57 | $533.75M | $509.39M – $558.1M | 9 |
| 2029 | $3.16 | $-0.85 – $15.70 | $1.91B | $46.73M – $7.73B | 3 |
| 2030 | $18.33 | $-4.91 – $91.11 | $4.86B | $119.13M – $19.7B | 3 |
